Psychedelics: Powerful Tools for Burdensome Disorders

SPECIAL REPORT: PSYCHEDELICS

The resurgence of interest in psychedelic drugs may represent a paradigm shift for psychiatry. Once relegated to the fringes of counterculture and stigmatized by decades of prohibition, psychedelics are now emerging as potent tools in the treatment of some of the most burdensome mental health disorders.

This Special Report in Psychiatric Times offers 3 articles—"Breaking Trauma: Mechanisms of MDMA-Assisted Psychotherapy for PTSD," "Psilocybin: A Clinician’s Guide to Pharmacological Interactions and Adverse Events," and "Psychedelics: Differences Across Substances and Context"—which collectively illuminate the promise and pitfalls of psychedelic-assisted therapies, providing essential insights for practitioners navigating this rapidly advancing field.

In the mid-20th century, clinical studies with lysergic acid diethylamide (LSD) and psilocybin suggested breakthroughs in treating alcoholism, anxiety, and depression. Humphrey Osmond coined the term psychedelic (mind-manifesting) to describe their profound effects on perception and cognition. However, the cultural upheavals of the 1960s, coupled with regulatory crackdowns, led to their classification as Schedule I drugs in the United States and worldwide by 1970, effectively halting research for nearly 3 decades. This moratorium not only stifled innovation but also perpetuated misconceptions about their risks and benefits.

Fast-forward to the 21st century, and a renaissance is underway: We have rigorous clinical trials, neuroimaging advancements, and a growing body of evidence supporting their therapeutic efficacy. Landmark approvals, such as the US Food and Drug Administration's breakthrough therapy designation for MDMA in treatment for posttraumatic stress disorder in 2017 and for psilocybin in treatment-resistant depression in 2018, underscore this momentum.^1,2 As of 2026, with ongoing phase 3 trials nearing completion, psychedelic drugs are poised to integrate into mainstream psychiatry, challenging traditional pharmacotherapies that require long-term daily tablet taking.

The first article, "Breaking Trauma: Mechanisms of MDMA-Assisted Psychotherapy for PTSD," dissects the neurobiological underpinnings of MDMA's therapeutic action. MDMA, or 3,4-methylenedioxymethamphetamine, facilitates emotional processing by modulating serotonin, dopamine, and norepinephrine systems, reducing amygdala hyperactivity while enhancing prefrontal cortex connectivity. This creates a "window of tolerance" for trauma reprocessing, allowing patients to confront memories without overwhelming fear. Drawing on data from Multidisciplinary Association for Psychedelic Studies-sponsored trials, which report remission rates exceeding 60% in patients with PTSD, the paper elucidates how MDMA-assisted sessions may promote neuroplasticity, foster empathy, and disrupt entrenched fear circuits. For clinicians, it offers practical frameworks for integrating this modality, emphasizing the synergy between pharmacology and psychotherapy in achieving lasting remission.

Complementing this, the second article, "Psilocybin: A Clinician’s Guide to Pharmacological Interactions and Adverse Events," provides a pragmatic road map for the safe implementation of psilocybin. Psilocybin primarily acts as a 5-HT_2A receptor agonist, inducing altered states that appear key to its antidepressant effects. However, as trials from institutions such as Johns Hopkins University and Imperial College London demonstrate, its benefits must be weighed against potential risks.

Finally, "Psychedelics: Differences Across Substances and Context" compares MDMA, psilocybin, LSD, ayahuasca, and others across pharmacological and experiential dimensions.

Together, these papers underscore the current potential for psychedelic innovation. They indicate the need for rigorous training, equitable access, and ongoing research if the promise is to be translated into practice. It is the most interesting and exciting time for mental health research in decades.

Dr Goodwin is the chief medical officer at Compass Pathways, as well as an emeritus professor of psychiatry and a National Institute for Health Research emeritus senior investigator at the University of Oxford, UK.

References

1. FDA grants breakthrough therapy designation for MDMA-assisted therapy for PTSD, agrees on special protocol assessment for phase 3 trials. News release. Multidisciplinary Association for Psychedelic Studies. August 26, 2017. Accessed January 15, 2026. https://maps.org/news/media/press-release-fda-grants-breakthrough-therapy-designation-for-mdma-assisted-psychotherapy-for-ptsd-agrees-on-special-protocol-assessment-for-phase-3-trials/

2. COMPASS Pathways receives FDA breakthrough therapy designation for psilocybin therapy for treatment-resistant depression. Compass Pathways. October 23, 2018. Accessed January 15, 2026. https://ir.compasspathways.com/News--Events-/news/news-details/2018/COMPASS-Pathways-receives-FDA-Breakthrough-Therapy-designation-for-psilocybin-therapy-for-treatment-resistant-depression/default.aspx